Weight Loss Drugs Market Shows Promising Growth
- Market Performance: In the first half of 2025, Wegovy and Zepbound ranked among the top 10 best-selling drugs globally, indicating strong demand and growth potential in the weight loss drug market, with projections suggesting more therapies will emerge in the next five years.
- Amgen's Drug Progress: Amgen's weight loss candidate MariTide achieved an average weight loss of up to 20% in a 52-week trial, and its monthly dosing convenience could attract more patients; it is expected to gain approval within three years, enhancing the company's product lineup.
- Roche's R&D Developments: Roche's anti-obesity drug CT-388 demonstrated a 22.5% weight loss effect in a 48-week trial and plans to initiate two phase 3 studies this quarter; if successful, it will provide new growth drivers and solidify Roche's position in the weight loss market.
- Investment Outlook: Both Amgen and Roche exhibit strong R&D capabilities and market potential in the weight loss drug sector, and considering their other drug product lines, investors may contemplate including their stocks in portfolios to capitalize on future growth opportunities.
Trade with 70% Backtested Accuracy
Analyst Views on AMGN
About AMGN
About the author

- Market Performance: The week was challenging for markets, but it concluded with a surge of optimism among investors.
- Dow 50K Discussion: The article focuses on the potential for the Dow Jones Industrial Average to reach the 50,000 mark, highlighting the factors that could contribute to this milestone.
- Investor Sentiment: Despite recent difficulties, there is a renewed sense of hope and positive sentiment in the market, suggesting a possible recovery.
- Future Outlook: Analysts are considering the implications of reaching the Dow 50K and what it could mean for the broader economy and investment strategies.
- Biosimilar Introduction: CVS Health announced that starting April 1, 2026, it will add osteoporosis biosimilars Ospomyv and Stoboclo, along with generic teriparatide products Bonsity and Tymlos, to its major national commercial formularies, providing patients with more cost-effective treatment options.
- Significant Cost Savings: Ed DeVaney, President of CVS Caremark, stated that the company has generated $1.5 billion in gross savings for customers and members by replacing Humira with biosimilars, demonstrating the value of formulary tools in driving competition.
- High Transition Success Rate: CVS Caremark reported that 96% of its clients using Humira successfully transitioned to a biosimilar, indicating effective support and guidance provided during the medication switch process.
- Formulary Update Process: CVS Specialty proactively contacts prescribers and patients during formulary changes to explain updates and guide them through the transition, ensuring patients receive timely access to necessary treatments.

Stock Market Surge: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge allowed the Dow to surpass the 50,000 mark for the first time in history.
Market Performance: The stock market experienced a significant rebound, with the Dow Jones Industrial Average increasing by over 1,000 points.
Historic Milestone: This surge pushed the Dow above 50,000 for the first time in history.

- Drug Listings: Many commonly prescribed brand-name drugs, including those for fertility and weight loss, are listed on TrumpRx.
- TrumpRx Overview: The platform appears to focus on providing information about various medications, particularly those associated with specific health conditions.
Website Launch: A new website named "TRUMP RX GOV" has been launched, focusing on topics related to former President Donald Trump.
Content Features: The website showcases various content, likely including news, updates, and commentary on Trump's political activities and policies.







